The Crohn's & Colitis Foundation collaborates with academic and industry researchers to help enroll patients with Crohn’s disease and ulcerative colitis into clinical studies. The list below highlights our partners' current research studies. Please note that these partners have paid to have their trials posted below, and the Crohn's & Colitis Foundation does not endorse any particular study.
For a comprehensive listing of all research studies currently recruiting, please visit our IBD Clinical Trial Finder.
This Stanford University study aims to identify potential environmental exposure markers that may contribute to the progression of Crohn's disease.
- We are conducting interviews with adults who have been clinically diagnosed with Ulcerative Colitis (UC) that is currently moderately-to-severely active based on clinician assessment.
- The focus of the interviews will be to gain a better understanding of the participant's experience living with ulcerative colitis, including what symptoms are most important to them and how these symptoms may impact their day-to-day life.
The purpose of this study is to test whether a non-invasive dietary intervention during the last trimester of pregnancy can beneficially shift the microbiome, or the bacterial flora of the body, in patients with Crohn’s disease and in their babies. Crohn's disease, a type of inflammatory bowel disease, is a chronic condition of the gastrointestinal tract that is associated with an imbalance in the gut microbiome. Diet may play a role in the development and treatment of Crohn's disease. Accumulating evidence suggests that maternal health and diet during pregnancy and early life have an impact on the baby’s microbiome composition and immune system development, with long-term health consequences, including establishing risk of developing Crohn's disease and other immune-mediated diseases. By changing the maternal microbiome during pregnancy through diet, we hope to be able to promote healthier immune system development in infants born to mothers with Crohn's disease.
The purpose of this study is to evaluate the clinical effectiveness (GALAXI 1), clinical and endoscopic effectiveness (GALAXI 2 and GALAXI 3) and safety of guselkumab in participants with Crohn's disease (CD).
We are conducting interviews with both caregivers of patients with CD and patients with CD between the ages of 5 and 17 years. Through these interviews, we will identify and explore the most important symptoms of CD experienced by children and adolescents. We want to understand how symptoms impact their lives and identify the specific language patients and their caregivers use to describe CD symptoms. With this data, we will create a conceptual model of CD, which will be used to develop a measure for Eli Lilly's clinical trials.
Full Study Title: A 52-Week, Multicenter, Randomized, Double-blind, Double-dummy, Placebo and Active-Controlled (Humira), Operationally Seamless Phase 2b/3, Parallel-group Study to Assess the Efficacy and Safety of Investigational drug in Participants With Moderately to Severely Active Crohn's Disease [INTREPID]
The primary objectives of this study is to evaluate the efficacy and safety of the investigational drug versus placebo (Stage 1) and versus Humira® (Stage 2) to achieve endoscopic response and clinical remission in participants with moderately to severely active Crohn's Disease (CD) who have failed or are intolerant to conventional therapy (corticosteroids or immunomodulators), or who are biological-treatment naive, have demonstrated a successful response to prior biological treatment, or who have failed or were intolerant to biological treatment.
To investigate the underlying mechanisms of sex differences in statural growth impairment and to develop a predictive model to identify patients at highest risk for developing growth impairment refractory to standard therapeutic approaches
This study is designed to evaluate the safety and efficacy of GS-5745 in patients with moderate to severely active ulcerative colitis and to determine the optimal dose for Induction and Maintenance therapy. Improvements in patient symptoms and an endoscopy will be measured to determine if the drug is working. In addition, this study will look at the relationship of noninvasive markers of disease activity with the blood levels of GS-5745.